NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced the creation of Revelation Neuro, Inc., a wholly owned private subsidiary dedicated to developing non-implantable AI-powered brain-computer interface (BCI) technology. Positioned at the forefront of neurorehabilitation advancements, Revelation Neuro aims to establish a gold standard in personalized therapeutic approaches for patients with motor and neurological dysfunction.
President and CEO of Helius, Dane Andreeff, highlighted the innovative vision behind the move, saying, “We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI-powered BCI. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option.”
Revelation Neuro will leverage Helius’ robust intellectual property portfolio and five years of clinical evidence comprising data from over 400 subjects to fuel its AI algorithm development. The subsidiary’s efforts will initially focus on motor function rehabilitation but hold broader potential to address conditions like cognitive deficits, mood disturbances, and behavior disorders.
“Revelation Neuro is focused on maximizing the positive effect of neuromodulation by applying AI to optimize individual response to translingual stimulation,” Andreeff added. “Helius’ extensive dataset provides a solid foundation to refine algorithms, paving the way for precise, personalized approaches to rehabilitation.”
Helius plans to assign its newly developed intellectual property and license its existing IP to Revelation Neuro. The subsidiary will advance its initiatives through external funding sources, with no significant additional capital investment anticipated from Helius. To date, Helius has invested over $70 million in its proprietary neuromodulation platform, which positions Revelation Neuro for expedited development.
Helius will also participate in the 37th Annual Roth Conference, with executives Dane Andreeff and Jeff Mathiesen presenting on Monday, March 17, 2025, at 12:00 p.m. PT. The presentation will be available via webcast on the company’s investor website.
The launch of Revelation Neuro spotlights Helius’ effort to lead advancements in neuromodulation and AI-powered therapeutic technologies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.